Don’t Put All Your Eggs in One Basket: Patent Claim Strategies for Medical Device and Consumer Health Companies

Why It Matters

A single, narrowly drafted patent can be dismantled in an IPR, leaving core products exposed and litigation vulnerable. Robust claim drafting and continuation practices are essential for maintaining competitive advantage in the fast‑moving health‑tech sector.

Key Takeaways

• Functional limits must be expressly claimed, not implied by structure
• Dependent claims should add value, not define the independent claim
• Teaching‑away arguments require clear discouragement in prior art
• Build multiple continuations: method, use, and structural claim sets

Pulse Analysis

Inter partes review (IPR) has become a decisive tool for challengers seeking to invalidate patents, especially in high‑volume sectors like medical devices and consumer health. While district courts still handle infringement disputes, the PTAB’s ability to stay litigation and render a final decision means that a single weak claim can collapse an entire enforcement strategy. Companies must therefore anticipate IPR exposure early, integrating defensive considerations into the drafting phase rather than treating them as an afterthought.

The First Quality v. Essity case illustrates three core drafting pitfalls. First, relying on the specification to imbue structural terms with functional meaning is a losing proposition; explicit functional language is required to survive claim construction challenges. Second, dependent claims that merely restate the independent claim’s limitations can signal that the broader claim is overly vague, inviting invalidity findings. Finally, "teaching away" arguments demand unmistakable discouragement in the prior art, a high bar that most patentees cannot meet without clear, structural differentiation. By embedding precise functional descriptors and ensuring dependent claims truly enhance scope, applicants can fortify their patents against PTAB scrutiny.

Beyond claim language, portfolio architecture is the long‑term safeguard. Continuation practice—filing method‑of‑manufacture, method‑of‑use, and alternative structural claims—creates a thicket that disperses risk across multiple patents. This approach not only provides fallback positions if one claim set is invalidated but also strengthens licensing leverage and deters competitors. For medical‑device and consumer‑health firms, investing in a diversified, well‑structured patent portfolio is no longer optional; it is a strategic imperative to protect revenue streams and sustain market leadership.